IL17A and psoriasis: Due to its anti-inflammatory and anti-angiogenic properties, the therapeutic use of IL-38 cytokine might represent an alternative approach to block IL-36R activation in psoriasis and in other IL-17/IL-36-dependent inflammatory diseases.